Mym3 – Validated Depression and Anxiety Monitor on iPhone

Mym3 is checklist that allows you to screen yourself for potential depression and anxiety symptoms including bipolar and PTSD. You can then have a personalized report shared with you about how your depression is affecting you. This checklist is like a progress report to see how well you’re coping over time.

This mobile version of the checklist is adapted from M-3 Information's existing Web site. It provides the same, scientifically validated, mental health questionnaire, optimized for smart phones.

There is a very important feature, potential life saver - for people in deep distress and at risk of suicide, mym3 provides a direct, one-button link to call a national suicide hotline.

Interactive applications of this sort, offering users validated medical assessment and feedback in real-time, has the potential to greatly improve the dynamics of healthcare delivery for individuals who might otherwise suffer in silence. The value of this technology to college and military populations, among others, is considerable.

The "mym3 app" is available to iPhone (telephone and data) and iTouch (data only) users through the Apple iTunes applications store, where it is for sale for $2.99. M-3 Information contributes a portion of the proceeds to Mental Health America.

Main Purpose of M-3 Checklist

The M3 website encourages individuals to complete the M3 Screen, a private, self-rated checklist for potential mood and anxiety symptoms. The checklist responses trigger a feedback page indicating each individual’s relative risk for Depression, an Anxiety Disorder, Bipolar Disorder and PTSD. The Screen responses and the resulting M3 analysis of risk may be printed, emailed, or securely accessed online by a designated health care professional, all at the discretion of the user.

The information provided by the M3 expedites and organizes a discussion between doctor and patient of relevant mental health issues at their next office visit, helping to direct the clinician toward a more accurate diagnosis. By providing parallel educational material for patients, the M3 encourages compliance and long-range follow-up of progress.

The M3 is not designed to diagnose illness on its own. Rather, it is meant to elicit symptoms that may indicate a psychiatric illness. Physicians must use the symptoms checklist responses and the risk assessment provided as a basis for formulating a diagnosis and treatment. The M3 website does provide physicians with supplemental information that guides them through this formulation, including relevant follow-up questions to ask. A medication overview chart clearly matches the choices of medications with the symptoms the drugs are intended to treat. There is an outline of each drug’s side effects and potentially harmful drug interactions. Based on this information, doctors can readily determine the most appropriate medication.

How Often?

If you are under ongoing medical or therapeutic treatment, you may need to monitor your progress. Once a treatment has begun, whether psychotherapy or medication, it is recommended to record your progress on a weekly basis for the first month, biweekly for months 2 and 3, and monthly thereafter. Checking in weekly for the entire duration of your therapy will certainly do no harm, but M3 does not endorse monitoring your symptoms more often than once a week.

M-3 Checklist Validation

Since the publication of the validation article in March, 2010 the M-3 Checklist has been taken by people in over 120 countries and all 50 states. The M-3 Checklist was validated in a study performed at the University of North Carolina and reported in the March 2010 issue of the Annals of Family Medicine. The study was based on the responses of 647 patients at the University of North Carolina Family Practice Medicine Clinic. Patients can track their M3 score on Microsoft HealthVault via

About M-3 Information, LLC

The M3 was developed by a team of mental health, strategic communications, and information management experts, including Robert M. Post, MD, head of the Bipolar Collaborative Network; Bernard M. Snyder, MD, assistant clinical professor of psychiatry at Georgetown University and a cognitive behavioral therapist; Michael L. Byer, director of M-3 Information; Larry Culpepper, MD, family practice program at Boston University; Gerald Hurowitz, MD, assistant clinical professor of psychiatry at Columbia University and a clinical psychopharmacologist. The free and private screener is available at and is independently funded by M-3 Information without pharmaceutical industry support.


Related Posts Plugin for WordPress, Blogger...